This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer andProstate Cancer and by the compound strategy of Antibodies. Each of these three individual parts isevaluated according to standardized criteria in a five pillar pipeline drug assessment methodology tocompare drug development strategies in oncology. This makes it easy to find and compare analysisnot only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This partextensively analyses their 210 identified drug targets, organized into 205 drug target strategies, andassesses them in eight different compound strategies in colorectal cancer.This part is based on the following publication:A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research andDevelopment to Market
Part II: Prostate Cancer
The prostate cancer report part comprises defined and up to date development strategies for 346prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This reportpart extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drugtarget strategies, and assesses them in prostate cancer.This part is based on the following publication:A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research andDevelopment to Market
Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date development strategies for531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased toMarketed. The report extensively analyses their 255 identified drug targets, organized into 266 drugtarget strategies, and assesses them in 75 cancer indications.
Triple Analysis: Colorectal Cancer, Prostate Cancer and Antibodies
1
This part is based on the following publication:The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route toConsider Your Options and Position of OthersThe report is written for you to understand and assess the impact of competitor entry andcorresponding changes to development strategies for your own portfolio products. It helps teams tomaximize molecule value by selecting optimal development plans and manage risk and uncertainty.The report serves as an external commercial advocate for pharmaceutical companies' pipeline andportfolio planning (PPP) in cancer by:* Providing you with competitive input to the R&D organization to guide development of earlyproduct ideas and ensure efforts are aligned with business objectives* Assisting you to make informed decisions in selecting cancer indications that are known to beappropriate for your drug's properties* Analyzing, correlating and integrating valuable data sources in order to provide accurate data forvaluation of pipeline, in-licensing and new business opportunities* Providing you with commercial analytic support for due diligence on in-licensing and acquisitionopportunities* Supporting development of integrative molecule, pathway and disease area strategies* Integrating knowledge for you to consider the therapeutic target for the highest therapeuticoutcome and return on investmentThis report provides systems, analytical and strategic support both internally to PPP and tostakeholders across your own organization. The report will also be an important part of creating andimplementing a market development plan for cancer drugs to insure that the optimal marketconditions exist by the time the products are commercialized.
Triple Analysis: Colorectal Cancer, Prostate Cancer and Antibodies
2
Table of Contents
Key Topics Covered:Part I: Colorectal Cancer
5.1 The Scope of this Report 286 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest TherapeuticOutcome and Return on Investment (210 Drug Targets) 32-4517 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugsby their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal CancerDrugs) 452-6998 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs byCompound Strategy (8 Compound Strategies) 700-7459 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipelineby Investigator (182 Companies) 746-1,03910 Disclaimer 104011 Drug Index 104112 Company Index 1050Figures: Includes 6 FiguresTables: Includes 242 TablesTotal Number of Pages: 1,056
Part II: Prostate Cancer
5.1 The Scope of this Report 286 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment(202 Drug Targets) 32-3837 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage ofDevelopment in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs) 384-4388 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by
Triple Analysis: Colorectal Cancer, Prostate Cancer and Antibodies
3
Search History:
Result 00 of 00
00 results for result for
p.
Triple Analysis: Colorectal Cancer, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in…
(More)
124
Reads
0
Readcasts
0
Embed Views
Get Scribd Mobile
To get Scribd mobile enter your number and we'll send you a link to the Scribd app for iPhone & Android.We've sent a link to the Scribd app. If you didn't receive it, try again.
We'll never share your phone number.
More From This User
Notes
Load more
